Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqGS:AUTL
Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
Autolus Therapeutics (NASDAQ:AUTL) Full Year 2023 Results
Key Financial Results
- Net loss: US$208.4m (loss widened by 40% from FY 2022).
- US$1.20 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Autolus Therapeutics EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%.
Looking ahead, revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 5.8% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for Autolus Therapeutics you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Autolus Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:AUTL
Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.
Adequate balance sheet and slightly overvalued.